Therapy resistance mechanisms in Ewing’s sarcoma family tumors Atif A. AhmedHamid ZiaLars Wagner Review Article 29 January 2014 Pages: 657 - 663
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer Hyun ChangSung Kwan ShinJoo-Hang Kim Original Article 22 February 2014 Pages: 665 - 671
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors Megumi Inada-InoueYuichi AndoYasutsuna Sasaki Original Article 24 January 2014 Pages: 673 - 683
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib Antonia KalykakiSofia AgelakiVassilis Georgoulias Original Article 04 February 2014 Pages: 685 - 693
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial Carlos R. BecerraRamon SalazarEmily K. Bergsland Original Article 01 February 2014 Pages: 695 - 702
Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer Hirofumi MukaiShunji TakahashiThe TED 11576 investigators Original Article 01 February 2014 Pages: 703 - 710
Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency Ying XinXiang-di ShenBin Chen Original Article 12 February 2014 Pages: 711 - 719
Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects Dongyang LiuJi JiangPei Hu Original Article 01 February 2014 Pages: 721 - 727
Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure Michelle A. RudekCathy Y. ChangJohn F. Deeken Original Article 02 February 2014 Pages: 729 - 736
Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer Valérie F. CossonVivian W. NgBert L. Lum Original Article 12 February 2014 Pages: 737 - 747
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS Tomokazu KishikiHiroaki OhnishiMasanori Sugiyama Original Article Open access 06 February 2014 Pages: 749 - 757
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors Matthias FreiwaldUlrike SchmidAlexander Staab Original Article 13 February 2014 Pages: 759 - 770
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy Mathilde FoedermayrMiriam SebestaRupert Bartsch Original Article 14 February 2014 Pages: 771 - 778
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients Fei-fei HanChang-long GuoLi-hong Liu Original Article 12 February 2014 Pages: 779 - 788
Pharmacokinetics of doxorubicin in pregnant women Rachel J. RyuSara EyalMary F. Hebert Original Article 15 February 2014 Pages: 789 - 797
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer Yee ChaoJan-Sing HsiehChung-Pin Li Original Article Open access 17 February 2014 Pages: 799 - 806
Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration Xue XiaoMei YangPeng Bai Original Article 18 March 2014 Pages: 807 - 818
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG) Filippos KoinisAristidis PolyzosVassilis Georgoulias Original Article 15 February 2014 Pages: 819 - 825
Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics Matthaeus StoehrChristian MozetGunnar Wichmann Original Article 23 February 2014 Pages: 827 - 837
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere Heloisa P. SoaresSoley BayraktarCaio M. Rocha-Lima Original Article 23 February 2014 Pages: 839 - 845
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer Goro NakayamaChie TanakaYasuhiro Kodera Original Article 28 February 2014 Pages: 847 - 855
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen Daniel E. CastellanoJoaquim BellmuntJoan Carles Clinical Trial Report 26 February 2014 Pages: 857 - 867
The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions Zeen TongUsha YerramilliGondi Kumar Short Communication 14 March 2014 Pages: 869 - 874
